Additional file 9 of Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017

Additional file 9. Changes in the mean daily doses of gabapentinoids among patients who discontinued OAT. Legends: CI = Confidence interval, df = degree of freedom, and OAT = opioid agonist therapy. 1) Paired samples t-test, df = 25, comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 2) Paired samples t-test, df = 6, comparing mean daily dose ≥0 - ≤90 days to baseline related to discontinuation. 3) Paired samples t-test, df = 6, comparing mean daily dose ≥0 - ≤90 days to ≥90 - < 0 days related to discontinuation. The tables a) and b) display the daily doses of dispensed pregabalin and gabapentin, respectively, in the following period related to the date of the last dispensation of an OAT opioids: 1) 180–90 days before discontinuation (baseline), 2) 90–0 days before discontinuation, and 3) 0–90 days after discontinuation. Discontinuation was defined as all patients on OAT who had the last dispensation of an OAT opioid in the period January 1, 2017, to September 30, 2017, and no dispensation until the end of March 31, 2018. The daily doses were stated in mean, median, 25 percentile, and 75 percentile.